Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/186232
Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Background The BCN02-trial combined therapeutic vaccination with a viral latency reversing agent (romidepsin, RMD) in HIV-1-infected individuals and included a monitored antiretroviral pause (MAP) as an efficacy read-out identifying individuals with an early or late (< or > 4weeks) viral-rebound. Integrated-omics analyses were applied prior treatment interruption to identify markers of virus control during MAP.& nbsp;Methods PBMC, whole-genome DNA methylation and transcriptomics were assessed in 14 BCN02 participants, including 8 Early and 4 Late viral-rebound individuals. Chromatin state, histone marks and integration analysis (his tone-3 acetylation (H3Ac), viral load, proviral levels and HIV-specific T cells responses) were included. REDUC-trial samples (n = 5) were included as a control group for RMD administration alone.& nbsp;Findings DNA methylation imprints after receiving the complete intervention discriminated Early versus Late viral rebound individuals before MAP. Also, differential chromatin accessibility and histone marks at DNA methylation level were detected. Importantly, the differential DNA methylation positions (DMPs) between Early and Late rebounders before MAP were strongly associated with viral load, proviral levels as well as the HIV-specific T-cell responses. Most of these DMPs were already present prior to the intervention and accentuated after RMD infusion.& nbsp;Interpretation This study identifies host DNA methylation profiles and epigenetic cascades that are predictive of subsequent virus control in a kick-and-kill HIV cure strategy. Copyright (C)& nbsp;2022 The Authors. Published by Elsevier B.V.& nbsp;
Matèries
Matèries (anglès)
Citació
Citació
ORIOL TORDERA, Bruna, ESTEVE CODINA, Anna, BERDASCO, María, ROSÁS UMBERT, Míriam, GONÇALVES, Elena, DURAN CASTELLS, Clara, CATALÀ MOLL, Francesc, LLANO, Anuska, CEDEÑO, Samandhy, PUERTAS CASTRO, Ma. carmen, TOLSTRUP, Martin, SØGAARD, Ole s., CLOTET, Bonaventura, MARTÍNEZ PICADO, Francisco javier, HANKE, Tomáš, COMBADIERE, Behazine, PAREDES, Roger, HARTIGAN-O'CONNOR, Dennis, ESTELLER, Manel, MEULBROEK, Michael, CALLE, María luz, SANCHEZ PLA, Alex, MOLTÓ, José, MOTHE, Beatriz, BRANDER, Christian, RUIZ RIOL, Marta. Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome. _eBioMedicine_. 2022. Vol. 78. [consulta: 21 de gener de 2026]. ISSN: 2352-3964. [Disponible a: https://hdl.handle.net/2445/186232]